Suppressed ER‐associated degradation by intraglomerular cross talk between mesangial cells and podocytes causes podocyte injury in diabetic kidney disease. Issue 11 (30th September 2020)

• Record Type: Journal Article
• Authors: Fujimoto, Daisuke; Kuwabara, Takashige; Hata, Yusuke; Umemoto, Shuro; Kanki, Tomoko; Nishiguchi, Yoshihiko; Mizumoto, Teruhiko; Hayata, Manabu; Kakizoe, Yutaka; Izumi, Yuichiro; Takahashi, Satoru; Mukoyama, Masashi
• Is Part Of: FASEB journal. Volume 34:Issue 11(2020)
• Page Start: 15577
• Page End: 15590
• Publication Date: 2020-09-30
• Subjects: diabetic nephropathy -- ERAD -- nephrin phosphorylation; Biology -- Periodicals; Biology, Experimental -- Periodicals; 570
• DOI: 10.1096/fj.202000078RR
• Languages: English
• ISSNs: 0892-6638

Abstract

Abstract: Mesangial lesions and podocyte injury are essential manifestations of the progression of diabetic kidney disease (DKD). Although cross‐communication between mesangial cells (MCs) and podocytes has recently been suggested by the results of single‐nucleus RNA sequencing analyses, the molecular mechanisms and role in disease progression remain elusive. Our cDNA microarray data of diabetic mouse glomeruli suggested the involvement of endoplasmic reticulum (ER) stress in DKD pathophysiology. In vitro experiments revealed the suppression of the ER‐associated degradation (ERAD) pathway and induction of apoptosis in podocytes that were stimulated with the supernatant of MCs cultured in high glucose conditions. In diabetic mice, ERAD inhibition resulted in exacerbated albuminuria, increased apoptosis in podocytes, and reduced nephrin expression associated with the downregulation of ERAD‐related biomolecules. Flow cytometry analysis of podocytes isolated from MafB (a transcription factor known to be expressed in macrophages and podocytes)‐GFP knock‐in mice revealed that ERAD inhibition resulted in decreased nephrin phosphorylation. These findings suggest that an intraglomerular cross talk between MCs and podocytes can inhibit physiological ERAD processes and suppress the phosphorylation of nephrin in podocytes, which thereby lead to podocyte injury under diabetic conditions. Therapeutic intervention of the ERAD pathway through the cross talk between these cells is potentially a novel strategy for DKD.